Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02277704 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
A Phase 2 study, sponsored by Tonix Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
NCT02277704 is a Phase 2 study that has completed, run by Tonix Pharmaceuticals. The registered enrollment target is 245 participants.
The verdict
NCT02277704, a Phase 2 study, has completed, sponsored by Tonix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
Study Summary
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible subjects will return regularly to the study clinic for weekly or biweekly visits for assessments of efficacy and safety.
Interventions
- DRUG Placebo
- DRUG TNX-102 SL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02277704
The ClinicalTrials.gov registry entry for NCT02277704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tonix Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02277704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02277704 about?
NCT02277704 is a clinical study titled "Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions". This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible subjects wi...
What is the current status of trial NCT02277704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2014-10. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02277704?
The interventions under investigation include: Placebo (DRUG), TNX-102 SL (DRUG).
Who is sponsoring clinical trial NCT02277704?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.